The decrease in BMD was correlated with longer treatment periods in the high-PRL group, rather than with PRL levels, suggesting that the duration of hyperprolactinaemia may have a greater impact than PRL levels themselves. This evidence concerns the gene PRL and hyperprolactinemia.